icon-    folder.gif   Conference Reports for NATAP  
 
  22nd Conference on Retroviruses and
Opportunistic Infections
Seattle Washington Feb 23 - 26, 2015
Back grey_arrow_rt.gif
 
 
 
Statin Therapy Reduces Coronary Noncalcified Plaque Volume
in HIV-infected Patients: a Randomized Controlled Trial
 
 
  Reported by Jules Levin
CROI 2015 Feb 23-26, Seattle, WA
 
"Statin therapy not only prevented the progression of coronary atherosclerosis, but it reduced overall plaque volume and especially lipid laden noncalcified plaque volume compared to placebo........Statin therapy reduced high risk morphology plaques.......Statin therapy was safe and well-tolerated........Due to technical limitations, statin effects on arterial inflammation by FDG-PET could not be adequately assessed, however atorvastatin did reduce systemic marker of vascular inflammation, Lp-PLA2
 
webcast:
 
http://www.croiwebcasts.org/console/player/25790?mediaType=slideVideo&
 
Janet Lo, Michael Lu, Ezinne Ihenachor, Jeffrey Wei, Sara Looby, Kathleen Fitch, Suhny Abbara, Gregory Robbins, Udo Hoffmann,
Steven Grinspoon
Massachusetts General Hospital
Harvard Medical School
Paris, Paris, France

CROI1.gif

CROI2.gif

CROI3.gif

CROI4.gif

CROI5.gif

CROI6.gif

CROI7.gif

CROI8.gif

CROI9.gif

CROI10.gif

Target to background ratio of FDG uptake in the aorta did not appear to change with statin therapy, however, we really cannot make a definitive conclusion due to technical limitations we faced using manual co-registration of PET and CT images of identical anatomical regions serially over time. Only 21 pairs of the co-registered scans were of acceptable image quality and thus greatly reducing our ability to analyze this endpoint.

CROI11.gif

*Calculated using CKDEPI formula. eGFR decreased significantly within the placebo group (p = 0.03), but not the Atorvastatin group (p = 0.83).

CROI12.gif

CROI13.gif